Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 16/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 16/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117193 | 0.86 | SCN1A (0.35) | SCN1ASCN8A | |
| SCHEMBL22163544 | 0.84 | AXL (0.36) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL22117274 | 0.84 | SCN1A (0.35) | SCN1ASCN8ASCN5A | |
| SCHEMBL22323213 | 0.83 | SCN1A (0.41) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL22117227 | 0.83 | SCN1A (0.35) | SCN1ASCN8ASCN5A | |
| SCHEMBL19968815 | 0.82 | SCN1A (0.39) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL29464855 | 0.82 | SCN1A (0.39) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL22163594 | 0.81 | — | — | |
| SCHEMBL24360868 | 0.77 | SCN1A (0.39) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL19927705 | 0.77 | SCN1A (0.38) | SCN1ASCN8ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071971-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-03-10 | — | — | US | disclosed |
| EP-3898621-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113227087-A | Macrocyclic compounds and their use in the treatment of disease | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020128925-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071971-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, PKD1, PKD2 | SCN1A 168/4885SCN8A 875/4885SCN5A 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.